A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy

被引：1
|
作者：
Villanueva, C. [1 ]
Awada, A. [2 ]
Campone, M. [3 ]
Machiels, J. P. [4 ]
Besse, T. [2 ]
Magherini, E. [5 ]
Dubin, F. [5 ]
Semiond, D. [5 ]
Pivot, X. [1 ]
机构：
[1] Hop Jean Minjoz, F-25030 Besancon, France
[2] Inst Jules Bordet, B-1000 Brussels, Belgium
[3] Ctr Rene Gauducheau, F-44035 Nantes, France
[4] Clin Univ St Luc, Ctr Canc, B-1200 Brussels, Belgium
[5] Sanofi Aventis, Paris, France
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70917-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：268 / 268
页数：1
相关论文
共 50 条
  • [21] Mitomycin-C (MMC) in combination with capecitabine (mixel) as third line chemotherapy in anthracycline and taxane pretreated metastatic breast cancer patients (MBC): Results of pilot study
    Maisano, Roberto
    Caristi, Nicola
    Mare, Marzia
    Mafodda, Antonino
    Iorfida, Monica
    Montalto, Erika
    Carboni, Rita
    Nardi, Mario
    ANNALS OF ONCOLOGY, 2005, 16 : 15 - 15
  • [22] Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T)
    Sylvester, L.
    Laufman, L.
    Jabboury, K.
    Saleh, M.
    Tkaczuk, K.
    Volterra, F.
    Arnott, J.
    Hannah, A.
    Sidor, C.
    Miller, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Phase I study of ixabepilone in combination with capecitabine in Japanese patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Watanabe, J.
    Horiguchi, J.
    Masuda, N.
    Aogi, K.
    Sato, R.
    Tokudome, T.
    Peck, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] A phase I study of BMS-247550 in combination with capecitabine in patients with metastatic breast cancer previously treated with a taxane and an anthracycline
    Thomas, E
    Bunnell, CA
    Vahdat, LT
    Schwartsberg, LS
    Gralow, JR
    Whitaker, LM
    Peck, R
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S83 - S83
  • [25] A phase I/II study of oral capecitabine (X) and vinorelbine (V) as second- or -third line chemotherapy in anthracycline/taxane pretreated patients (pts) with metastatic breast cancer (MBC).
    Kellokumpu-Lehtinen, P
    Sjoström, J
    Sunela, K
    Lehtinen, I
    Joensuu, H
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S70 - S70
  • [26] All oral combination of vinorelbine and capecitabine as a first line treatment in patients (pts) with metastatic breast cancer (MBC)
    Shehata, S.
    Khalaf, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Activity and safety of frontline docetaxel and capecitabine combination therapy in patients with metastatic breast cancer(MBC)
    Ceniti, S.
    Liguori, V.
    Turano, S.
    Biamonte, R.
    DeSimone, R.
    Filice, A.
    Manfredi, C.
    Mastroianni, C.
    Rovito, A.
    Viscomi, C.
    Palazzo, S.
    ANNALS OF ONCOLOGY, 2007, 18 : 47 - 47
  • [28] Phase II study of irinotecan plus capecitabine in patients with anthracycline and taxane pretreated metastatic breast cancer
    Lee, K. S.
    Ro, J.
    Park, I. H.
    Kim, E. A.
    Nam, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Weekly paclitaxel (TAX) and capecitabine (CAP) for metastatic breast cancer (MBC) patients (PTS) previously treated with anthracycline-containing therapy: A phase I dose-finding study.
    Susnjar, S
    Bosnjak, S
    Radulovic, S
    Stevanovic, J
    Gajic-Dobrosavljevic, M
    Kreacic, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 90S - 90S
  • [30] Pharmacogenetic study in patients (pts) with metastatic breast (MBC) and colorectal cancer (MCRC) treated with capecitabine (C)
    Alba, E.
    Ribelles, N.
    Sanchez, A.
    Lopez Siles, J.
    Sanchez, M. J.
    Gonzalez, E.
    Carabantes, F.
    Sanchez Rovira, P.
    Marquez, A.
    Sevilla, I.
    EJC SUPPLEMENTS, 2005, 3 (02): : 66 - 66
12345